Monitoring the safety of pioglitazone: Results of a prescription-event monitoring study of 12 772 patients in England

Drug Safety

Volumn 31, Issue 10, 2008, Pages 839-850

  Kasliwal, Rachna ^a,b   Wilton, Lynda V ^a,b   Shakir, Saad A W ^a,b  

^a DRUG SAFETY RESEARCH UNIT   (United Kingdom)

^b UNIVERSITY OF PORTSMOUTH   (United Kingdom)

Author keywords

Adverse drug reactions incidence; Pioglitazone, adverse reactions; Prescription event monitoring; Thiazolidinediones, adverse reactions; Type 2 diabetes mellitus

Indexed keywords

GLITAZONE DERIVATIVE; INSULIN; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; ROSIGLITAZONE; SULFONYLUREA; TROGLITAZONE;

ABDOMINAL PAIN; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; COHORT ANALYSIS; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; FATIGUE; FEMALE; FLUID RETENTION; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GENERAL PRACTITIONER; GLYCEMIC CONTROL; HEADACHE; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERGLYCEMIA; INSULIN RESISTANCE; LASSITUDE; LIVER FUNCTION TEST; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALAISE; MALE; MIGRAINE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PHARMACOEPIDEMIOLOGY; PRESCRIPTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RISK ASSESSMENT; SIDE EFFECT; UNITED KINGDOM; UPPER RESPIRATORY TRACT INFECTION; VISUAL DISORDER; VOMITING; WEIGHT GAIN;

ADOLESCENT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGE FACTORS; CHILD; COHORT STUDIES; DRUG PRESCRIPTIONS; ENGLAND; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INFANT, NEWBORN; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PATIENTS; PRODUCT SURVEILLANCE, POSTMARKETING; THIAZOLIDINEDIONES; TREATMENT OUTCOME;

EID: 50649121372     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200831100-00003     Document Type: Article

References (31)

1. Lenhard JM. PPAR gamma/RXR as a molecular target for diabetes. Receptors Channels 2001; 7 (4): 249-58
2. Wise J. Diabetes drug withdrawn after reports of hepatic events [letter]. BMJ 1997 Dec 13; 315 (7122): 1564
3. Scheen AJ. Hepatotoxicity with thiazolidinediones: is it a class effect? Drug Saf 2001; 24 (12): 873-88
4. Tolman KG. Thiazolidinedione hepatotoxicity: a class effect? Int J Clin Pract Suppl 2000 Oct; (113): 29-34
5. Takeda Europe R & D Centre Limited. Summary of Product Characteristics for Actos (pioglitazone hydrochloride); 2000 Oct
6. May LD, Lefkowitch JH, Kram MT, et al. Mixed hepatocellular-cholestatic liver injury after pioglitazone therapy. Ann Intern Med 2002 Mar 19; 136 (6): 449-52
7. Pinto AG, Cummings OW, Chalasani N. Severe but reversible cholestatic liver injury after pioglitazone therapy [letter]. Ann Intern Med 2002 Nov 19; 137 (10): 857
8. Maeda K. Hepatocellular injury in a patient receiving pioglitazone [letter]. Ann Intern Med 2001 Aug 21; 135 (4): 306
9. Chase MP, Yarze JC. Pioglitazone-associated fulminant hepatic failure. Am J Gastroenterol 2002 Feb; 97 (2): 502-3
10. Nagasaka S, Abe T, Kawakami A, et al. Pioglitazone-induced hepatic injury in a patient previously receiving troglitazone with success. Diabet Med 2002 Apr; 19 (4): 347-8
11. Farley-Hills E, Sivasankar R, Martin M. Fatal liver failure associated with pioglitazone [letter]. BMJ 2004 Aug 21; 329 (7463): 429
12. Macfarlane DP, Fisher M. Thiazolidinediones in patients with diabetes mellitus and heart failure: implications of emerging data. Am J Cardiovasc Drugs 2006; 6 (5): 297-304
13. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005 Oct 8; 366 (9493): 1279-89
14. Jamieson A, Abousleiman Y. Thiazolidinedione-associated congestive heart failure and pulmonary edema. Mayo Clin Proc 2004 Apr; 79 (4): 571-7
15. Kermani A, Garg A. Thiazolidinedione-associated congestive heart failure and pulmonary edema. Mayo Clin Proc 2003 Sep; 78 (9): 1088-91
16. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007 Jun 14; 356 (24): 2457-71
17. Lincoff AM, Wolski K, Nicholls SJ, et al. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007 Sep 12; 298 (10): 1180-8
18. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998 Sep; 21 (9): 1414-31
19. Shakir S. Prescription-event monitoring. In: Strom BL, editor. Pharmacoepidemiology. 4th ed. Chichester: John Wiley & Sons Ltd, 2005: 203-16
20. Strom B. Sample size considerations for pharmaco-epidemiology studies. In: Strom B, editor. Pharmaco-epidemiology. 2nd ed. Chichester: John Wiley & Sons, 1994
21. Machin D, Campbell M, Fayers P, et al. Chapter 7. Post marketing surveillance. Table 7.1. Sample sizes required to observe a single adverse reaction with a given probability and anticipated incidence. In: Machin D, editor. Sample size tables for clinical studies. 2nd ed. Oxford: Blackwell Science Ltd, 1997: 150
22. CIOMS W. International Ethical Guidelines for Biomedical Research Involving Human Subjects. 2002 [online]. Available from URL: http://www.cioms.ch/frame_guidelines_nov_200-2.htm [Accessed 2008 Jul 26]
23. Royal College of Physicians of London. Guidelines on the practice of Ethical Committees in Medical Research involving Human Subjects. 3rd ed. London: Royal College of Physicians, 1996
24. Department of Health. Supplementary operational guidelines for NHS Research Ethics Committees - November 2000. Multi-centre research in the NHS the process of ethical review when there is no local researcher [online]. Available from URL: http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/ PublicationsPolicyAndGuidance/DH_4006696. [Accessed 2008 Jul 26]
25. Brettenthaler N, De GC, Huber PR, et al. Effect of the insulin sensitizer pioglitazone on insulin resistance, hyperandrogenism, and ovulatory dysfunction in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004 Aug; 89 (8): 3835-40
26. Prasithsirikul W, Bunnag P. Improvement of fat redistribution, insulin resistance and hepatic fatty infiltration in HIV-associated lipodystrophy syndrome by pioglitazone: a case report. J Med Assoc Thai 2004 Feb; 87 (2): 166-72
27. Takeda UK Limited. Summary of Product Characteristics for Actos (pioglitazone hydrochloride), 2007 Aug [online]. Available from URL: http://emc.medicines.org.uk/industry/default.asp [Accessed 2008 Aug 19]
28. Erdmann E, Dormandy JA, Charbonnel B, et al. The effect of pioglitazone on recurrent myocardial infarction in 2,445 pa-tients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. J Am Coll Cardiol 2007 May 1; 49 (17): 1772-80
29. Gerrits CM, Bhattacharya M, Manthena S, et al. A comparison of pioglitazone and rosiglitazone for hospitalization for acute myocardial infarction in type 2 diabetes. Pharmacoepidemiol Drug Saf 2007 Oct; 16 (10): 1065-71
30. Larsen WJ. Human embryology. 2nd ed. New York: Churchill Livingstone Inc., 1997: 62-3
31. Reece EA, Hobbins JC. Diabetic embryopathy: pathogenesis, prenatal diagnosis and prevention. Obstet Gynecol Surv 1986 Jun; 41 (6): 325-35